Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Foley

Showing results (131-140 of 185) with videos related to

Pageof 19
Sort By:
International Journal of Dermatology|September 11, 2004
A prospective study of the use of cryosurgery for the treatment of actinic keratosesKeng-Ee Thai, Peter Fergin, Michael Freeman, et al.
The Journal of Investigative Dermatology|June 18, 2019
Guselkumab Efficacy after Withdrawal Is Associated with Suppression of Serum IL-23-Regulated IL-17 and IL-22 in Psoriasis: VOYAGE 2 StudyKenneth B Gordon, April W Armstrong, Peter Foley, et al.
Journal of Drugs in Dermatology : JDD|April 14, 2021
Effect of Ixekizumab on Patient Reported Outcomes and Quality of Life in Patients With Moderate-to-Severe Plaque Psoriasis: 5-Year Results from the UNCOVER-1 and -2 StudiesMelinda J Gooderham, Boni Elewski, Matthias Augustin, et al.
The British Journal of Dermatology|March 27, 2023
Bimekizumab maintenance of response through 3 years in patients with moderate-to-severe plaque psoriasis: results from the BE BRIGHT open-label extension trialBruce Strober, Yayoi Tada, Ulrich Mrowietz, et al.
The Australasian Journal of Dermatology|August 7, 2018
Psoriasis and infection. A clinical practice narrativeMarius Rademaker, Karen Agnew, Nicholas Anagnostou, et al.
The Australasian Journal of Dermatology|November 23, 2024
Australasian hidradenitis suppurativa management guidelinesJohn Frew, Annika Smith, Pablo Fernandez Penas, et al.
Leukemia & Lymphoma|October 30, 2009
IgA nephropathy associated with cutaneous T cell lymphomaAshish Bajel, Ming Yin Lin, Prudence A Hill, et al.
Journal of the American Academy of Dermatology|April 5, 2023
Malignancy rates through 5 years of follow-up in patients with moderate-to-severe psoriasis treated with guselkumab: Pooled results from the VOYAGE 1 and VOYAGE 2 trialsAndrew Blauvelt, Mark Lebwohl, Richard G Langley, et al.
Dermatology and Therapy|January 17, 2022
Effectiveness and Safety of Secukinumab for Psoriasis in a Real-World Clinical Setting in the Asia-Pacific and Middle East Regions: Results from the REALIA StudyPeter Foley, Tsen-Fang Tsai, Karl Rodins, et al.
The Australasian Journal of Dermatology|July 28, 2023
Australian consensus: Treatment goals for moderate to severe psoriasis in the era of targeted therapies - Adult patientsPeter Foley, Kurt Gebauer, John Sullivan, et al.
Pageof 19

Showing results (131-140 of 185) with videos related to

Sort By:
Pageof 19
International Journal of Dermatology|September 11, 2004
A prospective study of the use of cryosurgery for the treatment of actinic keratosesKeng-Ee Thai, Peter Fergin, Michael Freeman, et al.
The Journal of Investigative Dermatology|June 18, 2019
Guselkumab Efficacy after Withdrawal Is Associated with Suppression of Serum IL-23-Regulated IL-17 and IL-22 in Psoriasis: VOYAGE 2 StudyKenneth B Gordon, April W Armstrong, Peter Foley, et al.
Journal of Drugs in Dermatology : JDD|April 14, 2021
Effect of Ixekizumab on Patient Reported Outcomes and Quality of Life in Patients With Moderate-to-Severe Plaque Psoriasis: 5-Year Results from the UNCOVER-1 and -2 StudiesMelinda J Gooderham, Boni Elewski, Matthias Augustin, et al.
The British Journal of Dermatology|March 27, 2023
Bimekizumab maintenance of response through 3 years in patients with moderate-to-severe plaque psoriasis: results from the BE BRIGHT open-label extension trialBruce Strober, Yayoi Tada, Ulrich Mrowietz, et al.
The Australasian Journal of Dermatology|August 7, 2018
Psoriasis and infection. A clinical practice narrativeMarius Rademaker, Karen Agnew, Nicholas Anagnostou, et al.
The Australasian Journal of Dermatology|November 23, 2024
Australasian hidradenitis suppurativa management guidelinesJohn Frew, Annika Smith, Pablo Fernandez Penas, et al.
Leukemia & Lymphoma|October 30, 2009
IgA nephropathy associated with cutaneous T cell lymphomaAshish Bajel, Ming Yin Lin, Prudence A Hill, et al.
Journal of the American Academy of Dermatology|April 5, 2023
Malignancy rates through 5 years of follow-up in patients with moderate-to-severe psoriasis treated with guselkumab: Pooled results from the VOYAGE 1 and VOYAGE 2 trialsAndrew Blauvelt, Mark Lebwohl, Richard G Langley, et al.
Dermatology and Therapy|January 17, 2022
Effectiveness and Safety of Secukinumab for Psoriasis in a Real-World Clinical Setting in the Asia-Pacific and Middle East Regions: Results from the REALIA StudyPeter Foley, Tsen-Fang Tsai, Karl Rodins, et al.
The Australasian Journal of Dermatology|July 28, 2023
Australian consensus: Treatment goals for moderate to severe psoriasis in the era of targeted therapies - Adult patientsPeter Foley, Kurt Gebauer, John Sullivan, et al.
Pageof 19